Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA on Fear Extinction
NCT03527316Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Oct 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of midomafetamine in post-traumatic stress disorder (PTSD) (2 arms), sponsored by University Hospital Basel. Primary endpoints: Fear extinction measured by Skin conductance response at 12 months and Fear extinction measured by Fear-potentiated startle at 12 months. Started Oct 2019; status: completed.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03527316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03527316.